Precision Radiation Therapy Alone Doubles Historical Survival Rates for Inoperable Lung Cancer, Landmark Lancet Trial Finds
Why now
Thesis: Landmark trial, but no direct equity exposure
Catalyst to watch: Publication and guideline adoption
Main risk: Single trial, sponsor not identified
Why it matters
Trial results could shift lung-cancer treatment protocols, but no listed sponsor is named.
Details
New York Proton Center Chief Medical Officer Dr. Charles B. Simone II Serves as Co-First Author of Groundbreaking Phase III Trial Establishing 82% Two-Year Survival Benchmark NEW YORK, Sept. 24, 2026 /PRNewswire/ -- The New York Proton Center (NYPC), a global leader in proton therapy...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-24 12:01 UTC